enfortumab vedotin
seagen,astellas
['vedo', 'unite study', 'brca', ' vedo', 'urothelial', 'urothelial carcinoma', 'enfortumab', 'biomarker', 'bladder', ' uc,(-ucsd),(-ucsf),']
we start the day seeing a talk by tanya jindal, bs with biomarkers of response to unfortumab vedotin in patients with advanced urothelial carcinoma: analysis of the unite study, where they identified several potential biomarkers may help inform clinical decision. #ascogu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.